Interview: Pressures On US Generics Industry Go Beyond Current Price Squeeze

Generics firms in the US must fight back against brand industry attempts to thwart competition as well as regulatory obstacles looming on the horizon, while continuing to grapple with ongoing price erosion, says AAM president and CEO Chip Davis.

IV1812_Generics-01_Price-Pressures_1200.jpg
'Significant pressures threaten the future sustainability of competitive generic and biosimilar markets in the US' • Source: Shutterstock

With generics filling nine out of every 10 prescriptions in the US and enabling ever-growing savings that totaled $265 billion in 2017 alone, onlookers could be forgiven for seeing the US generics industry as an unmitigated success.

The US market is frequently cited by other territories around the world as an example to aspire to, demonstrating the...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Business

More from Generics Bulletin